Across TCGA pan-cancer cohorts, SPTAN1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPTAN1 data layer compared with 21 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPTAN1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPTAN1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where SPTAN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.655	0.429	<.001	84	view →
LUAD	DFS	Median	All	0.854	0.968	<.001	38	view →
CCRCC	OS	Tertile	III,IV	0.985	0.104	.024	8	view →
LSCC	DFS	Tertile	All	0.853	0.966	.025	2	view →
GBM	DFS	Tertile	All	0.881	0.652	.016	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SPTAN1 tumor-vs-normal RNA expression · all SPTAN1 data types